



REVIEW

Genetic causes of hypomagnesemia, a clinical overview

Daan H. H. M Viering^{1,2} · Jeroen H. F. de Baaij² · Stephen B. Walsh¹ · Robert Kleta^{1,3} · Detlef Bockenhauer^{1,3}

Received: 23 March 2016 / Revised: 2 May 2016 / Accepted: 4 May 2016 / Published online: 27 May 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Magnesium is essential to the proper functioning of numerous cellular processes. Magnesium ion (Mg^{2+}) deficits, as reflected in hypomagnesemia, can cause neuromuscular irritability, seizures and cardiac arrhythmias. With normal Mg^{2+} intake, homeostasis is maintained primarily through the regulated reabsorption of Mg^{2+} by the thick ascending limb of Henle's loop and distal convoluted tubule of the kidney. Inadequate reabsorption results in renal Mg^{2+} wasting, as evidenced by an inappropriately high fractional Mg^{2+} excretion. Familial renal Mg^{2+} wasting is suggestive of a genetic cause, and subsequent studies in these hypomagnesemic families have revealed over a dozen genes directly or indirectly involved in Mg^{2+} transport. Those can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in *CLDN16*, *CLDN19*, *CASR*, *CLCNKB*), Gitelman-like hypomagnesemias (*CLCNKB*, *SLC12A3*, *BSND*, *KCNJ10*, *FYXD2*, *HNFB1*, *PCBD1*), mitochondrial hypomagnesemias (*SARS2*, *MT-TI*, Kearns–Sayre syndrome) and other hypomagnesemias (*TRPM6*, *CNMM2*, *EGF*, *EGFR*, *KCNA1*, *FAM111A*). Although identification of these genes has not yet

changed treatment, which remains Mg^{2+} supplementation, it has contributed enormously to our understanding of Mg^{2+} transport and renal function. In this review, we discuss general mechanisms and symptoms of genetic causes of hypomagnesemia as well as the specific molecular mechanisms and clinical phenotypes associated with each syndrome.

Keywords Magnesium · Homeostasis · Hereditary · Kidney · Distal convoluted tubule · Thick ascending limb of Henle's loop

Introduction

Magnesium is a vital element for the human body and is involved in numerous biological processes. It is the second-most abundant intracellular cation (Mg^{2+}) in the human body and is crucial for the function of over 600 enzymes and regulation of the activity of several ion channels, as well as for stabilization of negatively charged molecules such as ATP, ADP, RNA and DNA (reviewed in [1]). In order to constantly suffice the body's requirements for this ion, there is a significant storage capacity for Mg^{2+} : an adult human body usually contains about 24 g of Mg^{2+} at any one time [1]. Blood serum only contains a fraction of this, with normal serum Mg^{2+} concentrations [Mg^{2+}] ranging from 0.70 to 1.1 mM, which translates to about 60 mg in total. Even though only two-thirds of this is biologically active (the ionized fraction), total serum Mg^{2+} concentrations are still used in daily practice as a measurement of the total Mg^{2+} status of a patient. Accordingly, hypomagnesemia is defined as a serum [Mg^{2+}] < 0.70 mM (< 1.7 mg/dL) and hypermagnesemia

✉ Robert Kleta
r.kleta@ucl.ac.uk

¹ Centre for Nephrology, University College London, London, UK
² Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
³ Paediatric Nephrology, Great Ormond Street Hospital, London, UK

as a serum $[Mg^{2+}] > 1.1$ mM (> 2.5 mg/dL). A shortage of Mg^{2+} can have direct consequences, some well-established, others less clear, but it is also associated with several other diseases. Direct consequences or symptoms that might arise from hypomagnesemia are variable in severity and may correlate to the extent and duration of the Mg^{2+} shortage, ranging from leg cramps and tiredness to seizures, coma and eventually death (Table 1). In addition, (severe) hypomagnesemia may have further consequences during pregnancy, as suggested by findings that a Mg^{2+} -deficient diet in pregnant mice was able to induce fetal malformations [2]. Conversely, supplementation with magnesium sulfate ($MgSO_4$) during pregnancy is a treatment for pre-eclampsia [3], suggesting a role for a relative shortage of Mg^{2+} in this disease too. Lastly, some diseases, such as Parkinson's disease and diabetes, have merely been associated with low serum Mg^{2+} concentrations (reviewed in [1]). It is not yet clear, however, whether hypomagnesemia is the cause, a consequence or simply an epiphenomenon in these diseases.

Most of our current knowledge about Mg^{2+} homeostasis has been obtained by studying the molecular mechanisms through which genetic mutations cause hypomagnesemia. The aim of this review is to provide an update of the currently known genetic defects in Mg^{2+} homeostasis from a clinical point of view, discussing firmly established knowledge as well as several recently discovered or neglected hereditary hypomagnesemic syndromes.

Table 1 Direct consequences of hypomagnesemia

Direct consequences of hypomagnesemia ^a
Chvostek and Trousseau's signs
Tiredness
Generalized weakness
Tremor
Paresthesias and palpitations
Hypokalemia
Hypoparathyroidism resulting in hypocalcemia
Chondrocalcinosis
Failure to thrive (in children)
Spasticity and tetany
Seizures
Electrocardiography changes, including prolonged QT interval (especially with concomitant hypokalemia)
Cardiac arrhythmias (especially with concomitant hypokalemia)
Basal ganglia calcifications
Coma
Intellectual disability
Death

^a Consequences of hypomagnesemia are presented from top to bottom of table in order of increasing severity

Maintaining Mg^{2+} homeostasis

The daily dietary Mg^{2+} intake recommended by the U.S. Institute of Medicine is dependent on age (Table 2). Approximately 30–50 % of the ingested Mg^{2+} will be absorbed by the intestine, although this has been reported to increase to 80 % in cases of Mg^{2+} deficiency. The bulk of the dietary Mg^{2+} is initially absorbed in the jejunum and ileum via paracellular pathways. The remainder can be absorbed by the colonic epithelium, entering the cells via transient receptor potential melastatin type 6 (TRPM6), an essential ion channel and serine/threonine-protein kinase, and probably exiting the cells at the basolateral side by making use of the sodium (Na^+) gradient and the Na^+ - Mg^{2+} exchanger cyclinM4 (CNNM4). Mg^{2+} subsequently enters the bloodstream to be delivered to cells, excreted by the kidneys or stored in bones. The large skeletal stores (50–60 % of total body Mg^{2+}) are in part responsible for keeping the serum Mg^{2+} concentrations constant (reviewed in [1]).

An even more important role in the regulation of Mg^{2+} homeostasis has been given to the kidney. After glomerular ultrafiltration, a mere 10–25 % of Mg^{2+} is reabsorbed by the proximal convoluted tubule (PCT) through paracellular pathways. Next, a further 50–70 % of the filtered Mg^{2+} is reabsorbed via paracellular pathways in the thick ascending limb of Henle's loop (TAL), where claudins play a key role in regulating paracellular calcium (Ca^{2+}) and Mg^{2+} transport [4] (see Fig. 1). Lastly, fine-tuning of the total Mg^{2+} reabsorption takes place in the distal convoluted tubule (DCT), which absorbs the final 5–10 % via transcellular pathways [5]. Essential for this last step is the apical Mg^{2+} channel TRPM6, the same channel that is responsible for Mg^{2+} transport in the large intestine (reviewed in [1]). The activity of this channel and its expression in the membrane are positively regulated through epidermal growth factor (EGF)-activated pathways [6] (see Fig. 1). Finally, also insulin, estrogen, extracellular pH, ATP, oxidative stress and Mg^{2+} itself are all found to be able to influence the magnitude of Mg^{2+} transport in the DCT [1]. Towards the end of this last segment, 95–99 %


Table 2 Recommended dietary allowance of magnesium (Mg^{2+})

Age (years)	RDA for males (mg Mg^{2+} /day)	RDA for females (mg Mg^{2+} /day) ^a
0-1	NA	NA
1-3	80	80
4-8	130	130
9-13	240	240
14-18	410	360
19-30	400	310
>31	420	320

RDA, Recommended dietary allowance; NA, information not available

^a For women during pregnancy the RDA is slightly higher

Fig. 1 Reabsorption of the magnesium cation (Mg^{2+}) in the thick ascending limb of Henle’s loop (TAL) and distal convoluted tubule (DCT). The relevant molecular transport mechanisms of the TAL and DCT are shown. Note that Mg^{2+} is transported via paracellular pathways into the TAL and via transcellular pathways into the DCT. A more detailed explanation of the molecular transport mechanisms can be found in the text. Black text indicates proteins that are mutated in genetic disorders of Mg^{2+} homeostasis. Grey text indicates other proteins



of filtered Mg^{2+} has been reabsorbed in total, and no further reabsorption takes place beyond this point [7].

Disturbances of Mg^{2+} homeostasis

Hypomagnesemia is defined as total serum Mg^{2+} concentrations below 0.70 mM (<1.7 mg/dL), while hypermagnesemia is reserved for concentrations above 1.1 mM (>2.7 mg/dL). Symptomatic hypermagnesemia is rare and mostly induced by excessive use of drugs which contain high amounts of Mg^{2+} , including laxatives and Epsom salts [1]. Hypomagnesemia on the other hand is more frequent [8–10] and can have several distinct causes. First among these is a prolonged general loss of electrolytes, such as during periods

of vomiting, diarrhea or malabsorption [11]. Secondly, several genetic disorders are accompanied by hypomagnesemia (see Table 4). Thirdly, albeit rare in the pediatric population, use of alcohol and certain drugs (Table 3; reviewed in [1]) should be considered. Lastly, contemporary food intake is relatively poor in Mg^{2+} [12] and may therefore contribute to the development of hypomagnesemia.

Diagnosing renal Mg^{2+} wasting

The most important clinical diagnostic tool for differentiating hypomagnesemia of renal origin from intestinal hypomagnesemia is determination of the fractional excretion of magnesium (FEMg) [13], which can be calculated with the

Table 3 Drugs associated with hypomagnesemia

Drugs associated with hypomagnesemia
Diuretics (furosemide, thiazide)
Epidermal growth factor receptor inhibitors (cetuximab)
Proton pump inhibitors (all, such as omeprazole)
Calcineurin inhibitors (cyclosporin A, tacrolimus)
Platinum derivatives (cisplatin, carboplatin)
Antimicrobials (aminoglycosides, pentimidine, rapamycin, amphotericin B, foscarnet)

following formula: $\{([Mg^{2+}]_{urine} \times [creatinine]_{plasma}) / (0.7 [Mg^{2+}]_{plasma} \times [creatinine]_{urine})\} \times 100$ %. The factor of 0.7 is included to adjust the total plasma Mg^{2+} concentration to the freely filtered fraction. A FEMg of >4 % in a hypomagnesemic patient is consistent with renal Mg^{2+} wasting, while a patient with a FEMg of <2 % will likely have an extra-renal origin of their hypomagnesemia [13]. However, a FEMg <4 % does not rule out renal Mg^{2+} wasting. First, a low glomerular filtration rate may result in a lower filtered load of Mg^{2+} . If the absorptive capacity of the kidney for Mg^{2+} is sufficient to cope with this lower load, the result may be a normal or even low FEMg. By the same mechanism, severe (renal) hypomagnesemia may result in a lower filtered load of Mg^{2+} and thus a normal or low FEMg. To account for these confounding factors, the serum Mg^{2+} levels of hypomagnesemic patients should be increased by means of intravenous Mg^{2+} supplementation before the FEMg is measured [14].

Hereditary hypomagnesemias

The genetic causes of hypomagnesemia are heterogeneous and comprise both recessive and dominant disorders (Table 4). The localization of the responsible genes is firmly established: all known genes encode proteins expressed in the DCT and/or TAL (Fig. 1). Nevertheless, the exact mechanisms at the molecular level remain to be elucidated for many of these diseases. We therefore propose four categories of genetic causes of hypomagnesemia based on similar manifestation, electrolyte abnormalities and localization. The resulting classes presumably also reflect a common pathophysiological mechanism for each group.

Hypercalciuric hypomagnesemias

The hypercalciuric hypomagnesemias are a class of hypomagnesemias in which the ability of the TAL to reabsorb divalent cations is affected. Ca^{2+} and Mg^{2+} reabsorption takes place via paracellular pathways in the TAL and is therefore strongly

dependent on the lumen positive transepithelial potential difference. Consequently, disruption of this voltage difference or of the integrity of this paracellular pathway will impair both Ca^{2+} and Mg^{2+} transport (reviewed in [4]). In two of the four types of Bartter syndrome, the lumen positive transepithelial voltage difference is decreased, while mutations in the *CASR*, *CLDN16* and *CLDN19* genes are proposed to interfere with the integrity of the pathway as well as the voltage difference [4]. Compensatory mechanisms in the DCT and other segments, however, may be able to avert hypomagnesemia (in Bartter syndrome type 1 and 2) or hypercalciuria (in Bartter syndrome type 4) [15]. This only leaves Bartter syndrome type 3, which impairs both TAL and DCT function (reviewed in [15]), as meeting the criterion for this group. Clinically, genetic disorders in this group can result in nephrocalcinosis or in chronic kidney disease (CKD), although the incidence and speed of progression differs from one to the other [4, 15].

CLDN16 and CLDN19 (familial hypomagnesemia with hypocalcemia and nephrocalcinosis)

Recessive mutations in *CLDN16* (encoding claudin-16) and *CLDN19* (encoding claudin-19) are the most frequent cause of hypercalciuric hypomagnesemia [16, 17]. These claudin mutations disrupt the pore selectivity of the tight junction, impairing paracellular Ca^{2+} and Mg^{2+} reabsorption in the TAL (reviewed in [18]). Consequently, patients suffer from hypomagnesemia and its associated symptoms, childhood nephrocalcinosis possibly due to the hypercalciuria and polyuria with polydipsia due to additional sodium (Na^+) and volume loss [19]. Patients with *CLDN19* mutations will also exhibit ocular anomalies [17]. The renal prognosis for both types is poor, with progressive CKD requiring renal replacement therapy typically in the second or third decade of life [20]. The cause of the CKD is unclear, although nephrocalcinosis may be a contributory factor.

CASR gain-of-function (autosomal dominant hypocalcemia with hypercalciuria)

Gain-of-function mutations in the gene encoding the calcium sensing receptor CaSR (*CASR*) are associated with hypercalciuric hypocalcemia and occasionally with hypomagnesemia [21, 22]. The two large exofacial lobes of the CaSR act as a peritubular Ca^{2+} and Mg^{2+} sensor in the TAL and other tissues (reviewed in [23]). Gain-of-function mutations, analogous to higher Ca^{2+} concentrations, cause the CaSR to suppress salt reabsorption in the TAL and interfere with the claudin-mediated pore selectivity in the tight junctions (reviewed in [23]). Hypercalciuric hypocalcemia with relative hypoparathyroidism is the most important symptom, which, especially when “mistreated” with vitamin D, can lead to nephrocalcinosis in certain cases (reviewed in [24]).

Table 4 Genetic causes of hypomagnesemia

Categories/names of disorders ^a	Gene	Protein	OMIM catalog number	Inheritance	Renal tubule segment	Plasma Mg ²⁺ concentration (mM) ^b	Estimated incidence or number of known families/patients	Distinctive findings, other than hypomagnesemia ^c
Hypocalcaemic hypomagnesaemias								
FHHNC type 1	<i>CLDN16</i>	Claudin-16	248250	R	TAL	0.49	100s of patients	Hypocalcaemia, nephrocalcinosis
FHHNC type 2	<i>CLDN19</i>	Claudin-19	248190	R	TAL	0.59	10s of patients	Polyuria/polydipsia, elevated serum iPTH, renal failure
ADHH Bartter syndrome type 5	<i>CASR</i>	CaSR	601198	D	TAL	0.66	100s of patients	Same as FHHNC type 1, plus ocular abnormalities
Bartter syndrome, type 3 (classical type)	<i>CLCNKB</i>	ClC-Kb	607634	R	DCT/TAL	0.63	100s of patients	Hypocalcaemia with normal or low PTH Gitelman-like phenotype possible, rarely nephrocalcinosis
Gitelman-like hypomagnesaemias								
Gitelman syndrome	<i>SLC12A3</i>	NCC	263800	R	DCT	0.49	1:40 000	Hypocalcaemia, hypokalemia, metabolic alkalosis
Bartter syndrome, type 4	<i>BSSND</i>	Barttin	602522	R	DCT/TAL	0.60	10s of patients	Chondrocalcinosis at older age
EAST syndrome	<i>KCNJ10</i>	Kir4.1	612780	R	DCT	0.63	26 patients	Prenatal complications, renal failure early in life possible
IDH	<i>FXYD2</i>	γ-subunit of the Na ⁺ -K ⁺ -ATPase	154020	D	DCT	0.47	3 families (29 patients)	Sensorineural deafness, seizures, ataxia
ADTKD/RCAD	<i>HNF1B</i>	HNF1β	137920	D	DCT	0.69	1:120 000	Renal, genital and pancreatic abnormalities and MODY5 in highly variable combination and presentation
HPABH4D/RCAD-like	<i>PCBD1</i>	PCBD1	264070	R	DCT	0.68	23 patients	MODY5-like
Mitochondrial hypomagnesaemias								
FHHH	<i>MT-TR</i>	Mt. tRNA ^{ile}	500005	Mt	DCT?	0.71	1 family (38 patients)	Variable
HUPRAS	<i>SARS2</i>	SARS2	613485	R	TAL?	0.37	2 families (4 patients)	Hypertension and hypercholesterolemia
KSS	Mitochondrial deletion	–	530000	Mt	TAL?	0.51	100s of patients	Hyperuricemia, pulmonary hypertension, renal failure and alkalosis
Other hypomagnesaemias								
HSH	<i>TRPM6</i>	TRPM6	602014	R	DCT	0.20	10s of patients	External ophthalmoplegia, retinopathy and cardiac conduction defects
IRH	<i>EGF</i>	EGF	611718	R	DCT	0.59	1 family (2 patients)	Variable
NISBD2	<i>EGFR</i>	EGFR	616069	R	DCT	?	1 patient	Neonatal presentation with severe hypomagnesemia
HSMR	<i>CNNM2</i>	CNNM2	613882	D/R	DCT	0.50	7 families (10 patients)	Intellectual disability
ADH/EA1	<i>KCNV1</i>	Kv1.1	176260	D	DCT	0.37	1 family (21 patients)	Severe inflammation of skin and bowel from birth
KCS2	<i>FAM111A</i>	FAM111A	127000	D	TAL?	0.46	10s of patients	Intellectual disability, seizures Episodic myokymia Impaired skeletal development and hypocalcaemic hypoparathyroidism

^a ADH, Autosomal dominant hypomagnesemia; ADHH, autosomal dominant hypocalcaemia with hypocalcaemia; ADTKD, autosomal dominant tubulointerstitial kidney disease; EA1, episodic ataxia type 1; EAST, epilepsy, ataxia, sensorineural deafness and tubulopathy; FHHNC, familial hypomagnesemia with hypocalcaemia and nephrocalcinosis; FHHH, hypertension, hypercholesterolemia and hypomagnesemia; HPABH4D, hyperphenylalaninemia BH4-deficient; HSH, hypomagnesemia with secondary hypocalcaemia; HSMR, hypomagnesemia with seizures and mental retardation; HUPRAS, hyperuricemia, pulmonary hypertension, renal failure and alkalotic syndrome; IDH, isolated dominant hypomagnesemia; IRH, isolated dominant hypomagnesemia; KCS2, Kenny–Chaffey syndrome type 2; KSS, Kearns-Sayre syndrome; NISBD2 neonatal inflammatory skin and bowel disease type 2; RCAD, renal cysts and diabetes; TAL, thick ascending limb of Henle’s loop; DCT distal convoluted tubule

^b Estimated average. To convert mM [Mg²⁺] to mg/dL, multiply by 2.43

^c iPTH, Intact parathyroid hormone; MODY5, maturity onset diabetes of the young type 5

Moreover, in patients with more severe gain-of-function of *CASR*, significant wasting of Mg^{2+} , Na^+ , potassium (K^+) and water can also occur [22]. This has led to the alternative name of Bartter syndrome type V in patients with this severe type of presentation [22].

CLCNKB (Bartter syndrome type III)

Homozygous or compound heterozygous mutations in *CLCNKB*, which encodes the chloride ion (Cl^-) channel *ClC-Kb*, cause Bartter syndrome type III. *ClC-Kb* is expressed basolaterally in the TAL and DCT, providing a pathway for (Cl^-) to exit the cell. Mutations in the channel therefore interfere with regulation of intracellular chloride levels and the function of NCC (thiazide-sensitive $NaCl$ cotransporter) and NKCC ($Na^+K^+Cl^-$ cotransporter) (reviewed in [15, 25] and [26]). Patients with mutations in *CLCNKB* often present during the first years of life, suffering from a Bartter-like phenotype, including hypercalciuria and loss of Na^+ , K^+ and water. When they grow older, however, a shift to a more Gitelman-like phenotype can be observed, with marked hypocalciuria and hypomagnesemia in addition to the loss of Na^+ , K^+ and water [25, 27]. The *CLCNKB* gene is thus listed under the hypercalciuric as well as under the Gitelman-like hypomagnesemias.

Gitelman-like hypomagnesemias

The genes from the second group of hypomagnesemias listed in Table 4, the Gitelman-like hypomagnesemias, all encode proteins that are involved in the transport of Na^+ , K^+ and/or Cl^- in the DCT. Adequate transcellular Mg^{2+} reabsorption in the DCT is dependent on the apical membrane potential, which is lumen positive when compared to the cytoplasm (reviewed in [28]). Therefore, Mg^{2+} reabsorption also depends on the intactness of other ion transport processes in the DCT. Alternatively, it has been proposed that atrophy of the DCT segment is responsible for all symptoms [29], although thiazide diuretics do not cause atrophy of the DCT [30]. Regardless of the mechanism underlying the DCT dysfunction, diseases from this group of hypomagnesemias all lead to increased calcium reabsorption along different nephron segments, proximal as well as distal (reviewed in [29]). This obviously results in hypocalciuria. In addition, the DCT dysfunction leads to fluid loss and a tendency to lower blood pressures despite an activated renin–angiotensin–aldosterone system (due to compensation mechanisms) (reviewed in [31]). Lastly, the relatively increased levels of aldosterone force the collecting duct to secrete potassium in exchange for sodium, leading to hypokalemia, which, in turn, leads to alkalosis. In addition, the combination of

hypomagnesemia with hypokalemia observed in this group can give rise to a prolonged QT interval and cardiac arrhythmias [32–34], justifying avoidance of drugs prolonging the QT interval [32].

SLC12A3 (Gitelman syndrome)

With an estimated prevalence of 1:40 000 [31], Gitelman syndrome is the most frequent genetic cause of hypomagnesemia. It is caused by recessive mutations in *SLC12A3*, the gene encoding the Na^+Cl^- -cotransporter (NCC) that is expressed on the apical membrane of the DCT [35] (reviewed in [31]). Symptoms are generally absent in the first years of life and only towards the end of the first decade do patients start to report symptoms [36]. Affected individuals can suffer from a range of hypomagnesemia-related symptoms, such as cramps, paresthesias or even cardiac arrest [32, 37]. In addition, they can suffer from the salt and water wasting that is apparent in most Gitelman-like hypomagnesemias, resulting in polyuria, salt craving and thirst [37]. The mechanism by which Gitelman syndrome causes hypomagnesemia is still not fully understood. One explanation can be found in the atrophy of the DCT that has been observed in a mouse model of Gitelman syndrome [29]. Additionally, a reduced apical membrane potential and a reduction in TRPM6 activation or mobilization could play a role. It may be speculated that the reduced apical membrane potential is caused by increased NHE2 (Na^+/H^+ exchanger)-mediated Na^+ reabsorption in the DCT as a means to compensate for the NCC dysfunction.

BSND (Bartter syndrome type IV)

Barttin, encoded by the *BSND* gene, is expressed in the ascending thin limb, TAL, DCT and inner ear as a subunit of the *ClC-Kb* and *ClC-Ka* Cl^- channels (reviewed in [15, 26]). Consequently, patients with recessive mutations in *BSND* or digenic mutations affecting both *ClC-Kb* and *ClC-Ka* will suffer from profound salt wasting in these three tubule segments as well as sensorineural deafness. In addition to complete deafness, Bartter syndrome type IV can be distinguished from the other types of Bartter syndrome by the initial lack of hypercalciuria. In addition, a significant number of patients will develop CKD (reviewed in [15, 26]). Most important for treatment is the adequate supplementation of fluids and sodium directly after birth, much alike all other types of salt-losing tubulopathies with antenatal presentation [38]. Long-lasting treatment with indomethacin can be considered to prevent failure to thrive and decrease renal salt and water wasting, but it should be realized that this treatment will be less effective than in patients with Bartter types I and II [39] and that this drug can cause renal side effects.

KCNJ10 (epilepsy, ataxia, sensorineural deafness and tubulopathy syndrome)

This syndrome, characterized by epilepsy, ataxia, sensorineural deafness and tubulopathy (referred to as EAST syndrome), is a rare recessive genetic disease affecting the K^+ channel Kir4.1 encoded by *KCNJ10* [40]. This protein is expressed in several tissues, including the central nervous system, inner ear and basolateral side of DCT cells and possibly also TAL cells (reviewed in [41, 42]). In the kidney it forms a basolateral K^+ channel that conducts outward K^+ currents, thus recycling the K^+ imported by the Na^+ - K^+ -ATPase. To aid in diagnosis, magnetic resonance imaging of the brain might show subtle changes, especially in the dentate nuclei of the cerebellum [41]. Patients show often pronounced ataxia and obligate sensorineural deafness. Lastly, although intellectual abilities seem to lag behind [43], it is difficult to assess the intelligence of these patients due to deafness and ataxia impairing both verbal and written communication [44].

FXYD2 (isolated dominant hypomagnesemia)

Only three families, all Belgian or Dutch, putatively descendants from a common founder [45], have been reported to carry the hypomagnesemia-causing *FXYD2* mutation. The *FXYD2* gene encodes the γ -subunit of the Na^+ - K^+ -ATPase [46]. The specific dominant mutation causes misrouting of this γ -subunit, thereby preventing the splice variant *FXYD2b* from assembling with the α - and β -subunit of the Na^+ - K^+ -ATPase [46]. Virtually all patients suffer from muscle cramps; additionally, several other hypomagnesemia-related symptoms can occur [45].

HNF1B (autosomal dominant tubulointerstitial kidney disease)

Heterozygous mutations in the *HNF1B* gene are associated with a multi-system disorder and considered to be the most common genetic cause of congenital anomalies of the kidney and urinary tract (CAKUT) (reviewed in [47, 48]). The *HNF1B* gene is situated in a region susceptible for genomic rearrangements, resulting in a high frequency of large deletions and de novo gene defects [47]. Mutations in this gene can be detrimental to normal development and function of the kidney, pancreas and genital tract [47], thus giving rise to a highly variable set of symptoms originating from these organs, including CAKUT and maturity onset diabetes in the young (MODY).

Hypomagnesemia is also one of these symptoms, occurring in up to 50 % of affected children [49] and sometimes being the first clinical manifestation [50]. Hypomagnesemia becomes more pronounced with increasing age of the patient and can be missed in affected young children. As a result,

HNF1B mutations are the most common cause of genetic hypomagnesemia for pediatric nephrologists. The current view is that *HNF1B* dysfunction leads to inadequate transcription of the *FXYD2* splice-isoform *FXYD2a*, which encodes the γ -subunit of the Na^+ - K^+ -ATPase [51]. The diagnosis is complicated by the large variability in presentation and the lack of a clear genotype–phenotype relationship [47]. If a patient is considered to suffer from *HNF1B*-ADTKD, the diagnosis should only be rejected if point-mutations as well as deletions and insertions in *HNF1B* have been properly excluded.

PCBD1 (renal cyst and diabetes-like)

Recessive mutations in *PCBD1* had long been identified to be responsible for transient neonatal hyperphenylalaninemia and primapterinuria (HPABH4D) [52], but no other symptoms of this genetic defect had been reported until recently. Re-evaluation of earlier identified patients with this syndrome revealed that hypomagnesemia and MODY5-like diabetes are later manifestations of *PCBD1* mutations [53, 54]. This finding also has implications for the importance of looking for alternative genetic diagnoses (including *PCBD1* mutations) if screening for mutations of *PAH* (phenylalanine hydroxylase) is negative after a positive result for the Guthrie test.

The neonatal phenotype can be explained by the failure of *PCBD1* to fulfil its role as an enzyme in the metabolism of aromatic acids. The complications appearing later in life are explained by the additional role of *PCBD1* as a dimerization factor for *HNF1A* and *HNF1B*, regulating their transcriptional activity (reviewed in [53]). This in turn would influence *FXYD2* transcription, causing hypomagnesemia. It should be noted, however, that the CAKUT phenotype often observed in *HNF1B* patients is not seen in *PCBD1*-disease due to a different expression pattern of these two proteins. Lastly, hypokalemia and hypocalciuria have not been reported in these patients. Still, it is placed here with the Gitelman-like hypomagnesemias based on the pathophysiological mechanism.

Mitochondrial hypomagnesemias

The mitochondrial hypomagnesemias, of which the pathophysiological mechanism is still unexplained, have a highly variable presentation. Their phenotype depends both on the nature of the mutation and the fraction of mitochondria affected in each tissue (reviewed in [55]). Some of the mitochondrial hypomagnesemias are associated with Gitelman-like electrolyte abnormalities [56], while others seem to affect TAL function [57–59]. Physiologically, both have a high energy requirement, although the DCT seems to be a better candidate since it has the most mitochondria [60]. Still needing to be clarified is which function of the mitochondrion is most important in Mg^{2+} homeostasis: is it the ATP that is necessary

to drive the $\text{Na}^+\text{-K}^+\text{-ATPase}$ and to activate *CNNM2* [61]? Or could its role in Ca^{2+} -signaling be key here?

MT-TI, SARS2, POLG1 and mitochondrial deletions/duplications

Impaired mitochondrial function might be associated with hypomagnesemia much more frequently than is currently realized. At least three distinct mitochondrial syndromes are accompanied by hypomagnesemia: (1) deletions in the mitochondrial genome as seen in Kearns–Sayre syndrome [62] (2) recessive mutations in the human gene *SARS2* [57] and (3) mutations in the mitochondrial tRNA^{Ile} gene *MT-TI* causing a syndrome with hypertension, hypercholesterolemia and hypomagnesemia [56]. An additional two cases of patients with hypomagnesemia and other mitochondrial diseases have also been identified (mutations in *POLG1* and the mitochondrial Pearson's syndrome [63, 64]). Since checking serum Mg^{2+} concentrations is not regular clinical practice, it would be interesting to investigate the genuine frequency of hypomagnesemia in patients with mitochondrial disease.

Other hypomagnesemias

The remaining disorders associated with hypomagnesemia are classified in this review as “other hypomagnesemias” due to their heterogenic nature. One of these is caused by mutations in *TRPM6*, which encodes the DCT-specific apical Mg^{2+} transporter TRPM6, resulting in an isolated hypomagnesemia (i.e. no other symptoms except secondary to the hypomagnesemia). Others, such as mutations in *EGF* and *EGFR* affect the activity and expression of this channel [6]. *FAM111A* is the only gene in this group of which the pathophysiological mechanism underlying the hypomagnesemia has received no attention at all.

TRPM6 (hypomagnesemia with secondary hypocalcemia)

Mutations in the gene for the DCT- and colon-specific apical Mg^{2+} channel, *TRPM6*, cause the most profound genetic hypomagnesemia [65, 66]. A measured serum Mg^{2+} concentration as low as 0.2 mM or even lower, as low as immeasurable levels, is not uncommon in these patients [14]. Consequently, patients often present with seizures within the first months of life [14]. A defect in the TRPM6 channel impairs epithelial Mg^{2+} resorption in the colon and DCT, thereby inhibiting uptake and stimulating wasting of Mg^{2+} , causing significant hypomagnesemia [67]. The secondary hypocalcemia often observed is probably caused by inhibition of the parathyroid gland by the hypomagnesemia, resulting in low levels of parathyroid hormone and eventually leading to hypocalcemia [68].

CNNM2 (hypomagnesemia with seizures and mental retardation)

CNNM2 is most highly expressed in the TAL, DCT and brain [69, 70], which explains the combination of hypomagnesemia with additional neurological symptoms (anatomical abnormalities, seizures and intellectual disability) seen in patients with dominant or sometimes recessive *CNNM2* mutations [71]. Although *CNNM2* was first thought to be a basolateral Mg^{2+} transporter itself, it is now thought to fulfill the role of intracellular Mg^{2+} sensor by undergoing a conformational change upon binding of Mg-ATP [61]. How this conformational change eventually leads to the observed decrease in Mg^{2+} transport, however, remains unclear, as is the precise basis of the neurological symptoms.

EGF and EGFR (isolated recessive hypomagnesemia)

One mutation in the epidermal growth factor gene (*EGF*) has been associated with a recessive form of hypomagnesemia with an additional neurological phenotype (including intellectual disability) [72]. The only mutation identified to date interferes with proper trafficking of pro-EGF, which is expressed in TAL and DCT cells, resulting in a decreased peritubular concentration of autocrine EGF [72]. Subsequently, the signaling cascade from the EGF receptor (EGFR) to the Akt-mediated activation of Rac1 is turned off, resulting in a decrease of endomembrane trafficking of TRPM6 to the apical surface and decreased Mg^{2+} transport [6]. The intellectual disability on the other hand remains unexplained.

Since *EGF* mutations and cetuximab (an EGFR inhibitor) both cause hypomagnesemia [73], it is not surprising that mutations in *EGFR* have also been found to cause hypomagnesemia. Only one patient has been diagnosed to date with loss-of-function of the EGFR. This mutation resulted in severe symptoms comparable to those observed with full EGFR blockade, including skin rash, inflammation of the lungs and bowel and hypomagnesemia [74].

KCNA1 (autosomal dominant hypomagnesemia)

Intriguingly, only one mutation (identified with linkage in a large pedigree) in *KCNA1* has been associated with hypomagnesemia [75], while all other *KCNA1* mutations known to date cause episodic ataxia type 1 without hypomagnesemia (reviewed in [76]). The *KCNA1* gene encodes the voltage-gated K^+ channel Kv1.1 [75], which is abundantly expressed in certain neurons as well as on the apical membrane of cells in the DCT ([75] and reviewed in [77]). In neurons, the mutations in *KCNA1* impair normal repolarization of the membrane potential, resulting in stress-triggered episodes of ataxia and myokymia [77]. Following the same line of reasoning, one might speculate that genetic defects in Kv1.1 might cause

hypomagnesemia by depolarizing the apical DCT membrane [78]. However, this theory does not explain why other *KCNA1* mutations have not been reported to cause hypomagnesemia. Also, how does a voltage-gated K⁺-channel like *KCNA1*, which is closed and thus non-functional at normal apical membrane potential, cause hypomagnesemia in the first place?

FAM111A

Mutations in *FAM111A* are associated with two distinct dominant diseases: a perinatally lethal disorder called gracile bone dysplasia (GLCEB) and Kenny–Caffey syndrome type 2 (KCS2) [79]. To date, only KCS2 has been associated with hypomagnesemia [80–85]. Other symptoms of KCS2 include severe proportionate short stature, radiological bone anomalies, eye abnormalities and hypocalcemia owing to hypoparathyroidism (reviewed in [82]). *FAM111A* has been reported to be a host-range restriction factor [86] and shown to be an important component of the cell’s replication machinery near DNA forks, consistent with its proposed role in cancer and cell survival [87–89]. However, it is unclear how this function would link to hypomagnesemia. Alternatively, it might be speculated that its function is related to the function of *TBCE* [90], the causative gene for the clinically closely related Kenny–Caffey syndrome type 1 [91].

Treatment

Oral or intravenous Mg²⁺ supplementation is the only treatment available for hypomagnesemia of genetic origin. In the

acute situation of a (severely) symptomatically hypomagnesemic patient, intravenous Mg²⁺ supplementation can be very important. For adults, a dose of 8–12 g of MgSO₄ (containing 0.8–1.2 g of Mg²⁺) in the first 24 h is recommended, followed by 4–6 g/day for 3 or 4 days [92]. For the non-acute setting, oral Mg²⁺ supplementation of 3 × 120 mg/day is more convenient while being sufficiently effective [93]. Parenteral and oral Mg²⁺ supplementation is therefore recommended in many of the hypomagnesemias, including Gitelman syndrome, Bartter syndrome, EAST syndrome and those caused by *TRPM6* mutations [14, 31, 41]. The resulting rise in serum Mg²⁺ concentration often alleviates symptoms, such as seizures and secondary hypocalcemia, even though normal Mg²⁺ values are rarely reached [14, 75]. Further correction of the hypomagnesemia is generally impeded by the gastro-intestinal side effects frequently associated with oral Mg²⁺ supplementation. Paradoxically, higher doses of oral Mg²⁺ might even be detrimental because of the resulting diarrhea [31]. Also, attention should be given to the type of oral Mg²⁺ supplementation given since some preparations have a better bioavailability than others. For this reason, we recommend magnesium chloride or magnesium glycerophosphate rather than magnesium oxide or magnesium sulfate for oral Mg²⁺ supplementation [31].

Since hypokalemia is commonly associated with hypomagnesemia, especially in the Gitelman-like hypomagnesemias, one might consider treatment with the epithelial Na⁺ channel ENaC or aldosterone blockers. However, care should be taken, especially in the young child, since this treatment will interfere with the distal compensatory salt reabsorption of the kidney [27]. Lastly, seizures are a known result of several




Fig. 2 Diagnostic flowchart for a suspected genetic cause of hypomagnesemia. This diagnostic flowchart is primarily provided to give an impression of the clinical characteristics of all known genetic

causes of hypomagnesemia. Genetic testing can confirm or reject a diagnosis. Asterisks indicate dominantly inherited disorders

genetic hypomagnesemias, as a primary effect of the genetic defect or secondary to the Mg^{2+} deficiency. In both cases, treatment with anticonvulsants such as valproate or phenobarbital might be beneficial [41].

Summary and future perspectives

In summary, the identification of the different genetic hypomagnesemias has aided our understanding of the important role of the kidney—the TAL and DCT in particular—in maintaining Mg^{2+} homeostasis. Based on the combination of increased fractional renal Mg^{2+} excretion with familial occurrence and a variety of additional symptoms, it is possible to recognize cases with a genetic cause and differentiate between them to a certain extent (see Fig. 2). Subsequent characterization of the affected genes and proteins has improved our understanding of which molecular pathways are involved in Mg^{2+} homeostasis. Hypercalciuric hypomagnesemia is thereby often the presentation of a defect in the TAL, while Gitelman-like and “other” hypomagnesemias are generally localized to the DCT. Treatment still depends on Mg^{2+} supplementation, but an increased understanding of the pathophysiological mechanisms might make discovery of new treatment opportunities possible in the future.

Additional fundamental research might further elucidate the mechanisms of transport and regulation exploited by the DCT and TAL to maintain Mg^{2+} homeostasis. Not only does the basolateral Mg^{2+} transporter need to be identified, but the precise pathophysiological mechanisms by which known mutations cause hypomagnesemia also need further clarification. This even holds true for several well-known and thoroughly described hypomagnesemias, such as Gitelman syndrome. After all, some observations cannot be explained by current understanding. The proposed atrophy of the DCT, for example, has been observed in mice with Gitelman syndrome [29], but it is not present in mice on chronic thiazide treatment-induced hypomagnesemia [30]. The proposed decisive role for the membrane potential of the apical membrane is also not completely satisfying, especially since its role is proven for only some of the genetic hypomagnesemias [78].

On the other hand, some pathways linked to hypomagnesemia might be underestimated. The EGF/EGFR pathway and the insulin and estrogen pathways seem to be of significant importance in terms of increasing Mg^{2+} transport but there is currently little evidence linking them to hypomagnesemic pathology (reviewed in [1]). Additionally, the role of the Na^+K^+ -ATPase might be more important than currently appreciated. The Na^+K^+ -ATPase is known to occupy a central position in many of the Gitelman-like hypomagnesemia, while it has the potential of being involved in EGFR activation by means of the Na^+K^+ -ATPase-Src-kinase complex [94]. The pathophysiology underlying mitochondria-associated

diseases might also be of great interest since at least one of the other hypomagnesemias has been reported to be characterized by a vastly diminished size and number of mitochondria in the DCT cells [95]. However, it is not yet clear whether this is a cause, epiphenomenon or result of the hypomagnesemia. Lastly, the recent breakthroughs in identifying new pathways involved in Na^+ regulation by the DCT [96] could also shed new light on the transport of other ions in this segment. Identification of these other pathways will hopefully provide decisive evidence on the mechanisms of Mg^{2+} reabsorption in the kidney and might open new roads to causal treatment of hypomagnesemia.

Acknowledgments This work was supported by The European Union, FP7 (grant agreement 2012-305608, “European Consortium for High-Throughput Research in Rare Kidney Diseases (EURenOmics)).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. de Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. *Physiol Rev* 95:1–46
2. Schlegel RN, Cuffe JS, Moritz KM, Paravicini TM (2015) Maternal hypomagnesemia causes placental abnormalities and fetal and postnatal mortality. *Placenta* 36:750–758
3. Hall DG (1957) Serum magnesium in pregnancy. *Obstet Gynecol* 9:158–162
4. Hou J, Goodenough DA (2010) Claudin-16 and claudin-19 function in the thick ascending limb. *Curr Opin Nephrol Hypertens* 19:483–488
5. Brunette MG, Vigneault N, Carriere S (1974) Micropuncture study of magnesium transport along the nephron in the young rat. *Am J Physiol* 227:891–896
6. Thebault S, Alexander RT, Tiel Groenestege WM, Hoenderop JG, Bindels RJ (2009) EGF increases TRPM6 activity and surface expression. *J Am Soc Nephrol* 20:78–85
7. Dimke H, Hoenderop JG, Bindels RJ (2010) Hereditary tubular transport disorders: implications for renal handling of Ca^{2+} and Mg^{2+} . *Clin Sci (Lond)* 118:1–18
8. Syedmoradi L, Ghasemi A, Zahediasl S, Azizi F (2011) Prevalence of hypo- and hypermagnesemia in an Iranian urban population. *Ann Hum Biol* 38:150–155
9. Whang R, Ryder KW (1990) Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine. *JAMA* 263:3063–3064
10. Wong ET, Rude RK, Singer FR, Shaw ST Jr (1983) A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. *Am J Clin Pathol* 79:348–352

11. Tong GM, Rude RK (2005) Magnesium deficiency in critical illness. *J Intensive Care Med* 20:3–17
12. Worthington V (2001) Nutritional quality of organic versus conventional fruits, vegetables, and grains. *J Altern Complement Med* 7:161–173
13. Elisaf M, Panteli K, Theodorou J, Siamopoulos KC (1997) Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. *Magnes Res* 10:315–320
14. Schlingmann KP, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, Lotan D, Syrrou M, Prebble JJ, Cole DE, Metzger DL, Rahman S, Tajima T, Shu SG, Waldegger S, Seyberth HW, Konrad M (2005) Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. *J Am Soc Nephrol* 16:3061–3069
15. Jeck N, Schlingmann KP, Reinalter SC, Komhoff M, Peters M, Waldegger S, Seyberth HW (2005) Salt handling in the distal nephron: lessons learned from inherited human disorders. *Am J Physiol Regul Integr Comp Physiol* 288:R782–795
16. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP (1999) Paracellin-1, a renal tight junction protein required for paracellular Mg²⁺ resorption. *Science* 285:103–106
17. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppner H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhauss SC, Nurnberg P, Weber S (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. *Am J Hum Genet* 79:949–957
18. Yu AS (2015) Claudins and the kidney. *J Am Soc Nephrol* 26:11–19
19. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Schärer K, Seyberth HW, Konrad M (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 12:1872–1881
20. Konrad M, Hou J, Weber S, Dotsch J, Kari JA, Seeman T, Kuwertz-Broking E, Peco-Antic A, Tasic V, Dittrich K, Alshaya HO, von Vigier RO, Gallati S, Goodenough DA, Schaller A (2008) CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 19:171–181
21. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. *N Engl J Med* 335:1115–1122
22. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T (2002) Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. *Lancet* 360:692–694
23. Alfadda TI, Saleh AM, Houillier P, Geibel JP (2014) Calcium-sensing receptor 20 years later. *Am J Physiol Cell Physiol* 307: C221–231
24. Tyler Miller R (2013) Control of renal calcium, phosphate, electrolyte, and water excretion by the calcium-sensing receptor. *Best Pract Res Clin Endocrinol Metab* 27:345–358
25. Jeck N, Konrad M, Peters M, Weber S, Bonzel KE, Seyberth HW (2000) Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. *Pediatr Res* 48:754–758
26. Hebert SC (2003) Bartter syndrome. *Curr Opin Nephrol Hypertens* 12:527–532
27. Kleta R, Bockenhauer D (2006) Bartter syndromes and other salt-losing tubulopathies. *Nephron Physiol* 104:p73–80
28. McCormick JA, Ellison DH (2015) Distal convoluted tubule. *Compr Physiol* 5:45–98
29. Loffing J, Vallon V, Loffing-Cueni D, Aregger F, Richter K, Pietri L, Bloch-Faure M, Hoenderop JG, Shull GE, Meneton P, Kaissling B (2004) Altered renal distal tubule structure and renal Na(+) and Ca(2+) handling in a mouse model for Gitelman's syndrome. *J Am Soc Nephrol* 15:2276–2288
30. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ (2005) Enhanced passive Ca²⁺ reabsorption and reduced Mg²⁺ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. *J Clin Invest* 115:1651–1658
31. Knoers NV, Levchenko EN (2008) Gitelman syndrome. *Orphanet J Rare Dis* 3:22
32. Foglia PE, Bettinelli A, Tosetto C, Cortesi C, Crosazzo L, Edefonti A, Bianchetti MG (2004) Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). *Nephrol Dial Transplant* 19:1398–1402
33. Malafronte C, Borsa N, Tedeschi S, Syren ML, Stucchi S, Bianchetti MG, Achilli F, Bettinelli A (2004) Cardiac arrhythmias due to severe hypokalemia in a patient with classic Bartter disease. *Pediatr Nephrol* 19:1413–1415
34. Topol EJ, Lerman BB (1983) Hypomagnesemic torsades de pointes. *Am J Cardiol* 52:1367–1368
35. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitelman HJ, Lifton RP (1996) Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. *Nat Genet* 12:24–30
36. Scholl UI, Dave HB, Lu M, Farhi A, Nelson-Williams C, Listman JA, Lifton RP (2012) SeSAME/EAST syndrome—phenotypic variability and delayed activity of the distal convoluted tubule. *Pediatr Nephrol* 27:2081–2090
37. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB (2001) Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. *Kidney Int* 59:710–717
38. Azzi A, Chehade H, Deschenes G (2015) Neonates with Bartter syndrome have enormous fluid and sodium requirements. *Acta Paediatr* 104:e294–299
39. Seyberth HW, Schlingmann KP (2011) Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. *Pediatr Nephrol* 26:1789–1802
40. Bockenhauer D, Feather S, Stanescu HC, Bandulik S, Zdebek AA, Reichold M, Tobin J, Lieberer E, Sterner C, Landoure G, Arora R, Sirimanna T, Thompson D, Cross JH, van't Hoff W, Al Masri O, Tullus K, Yeung S, Anikster Y, Klootwijk E, Hubank M, Dillon MJ, Heitzmann D, Arcos-Burgos M, Knepper MA, Dobbie A, Gahl WA, Warth R, Sheridan E, Kleta R (2009) Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. *N Engl J Med* 360:1960–1970
41. Cross JH, Arora R, Heckemann RA, Gunny R, Chong K, Carr L, Baldeweg T, Differ AM, Lench N, Varadkar S, Sirimanna T, Wassmer E, Hulton SA, Ognjanovic M, Ramesh V, Feather S, Kleta R, Hammers A, Bockenhauer D (2013) Neurological features of epilepsy, ataxia, sensorineural deafness, tubulopathy syndrome. *Dev Med Child Neurol* 55:846–856
42. Zhang C, Wang L, Su XT, Lin DH, Wang WH (2015) KCNJ10 (Kir4.1) is expressed in the basolateral membrane of the cortical thick ascending limb. *Am J Physiol Renal Physiol* 308(11):F1288–296
43. Scholl UI, Choi M, Liu T, Ramaekers VT, Hausler MG, Grimmer J, Tobe SW, Farhi A, Nelson-Williams C, Lifton RP (2009) Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. *Proc Natl Acad Sci USA* 106:5842–5847

44. Bandulik S, Schmidt K, Bockenhauer D, Zdebek AA, Humberg E, Kleta R, Warth R, Reichold M (2011) The salt-wasting phenotype of EAST syndrome, a disease with multifaceted symptoms linked to the KCNJ10 K⁺ channel. *Pflugers Arch* 461:423–435
45. de Baaij JH, Dorresteijn EM, Hennekam EA, Kamsteeg EJ, Meijer R, Dahan K, Muller M, van den Dorpel MA, Bindels RJ, Hoenderop JG, Devuyst O, Knoers NV (2015) Recurrent FXD2 p.Gly41Arg mutation in patients with isolated dominant hypomagnesaemia. *Nephrol Dial Transplant* 30:952–957
46. Meij IC, Koenderink JB, van Bokhoven H, Assink KF, Groenestege WT, de Pont JJ, Bindels RJ, Monnens LA, van den Heuvel LP, Knoers NV (2000) Dominant isolated renal magnesium loss is caused by misrouting of the Na(+), K(+)-ATPase gamma-subunit. *Nat Genet* 26:265–266
47. Clissold RL, Hamilton AJ, Hattersley AT, Ellard S, Bingham C (2015) HNF1B-associated renal and extra-renal disease—an expanding clinical spectrum. *Nat Rev Nephrol* 11:102–112
48. Bockenhauer D, Jaureguierry G (2015) HNF1B-associated clinical phenotypes: the kidney and beyond. *Pediatr Nephrol* 31:707–714
49. Adalat S, Woolf AS, Johnstone KA, Wirsing A, Harries LW, Long DA, Hennekam RC, Ledermann SE, Rees L, van't Hoff W, Marks SD, Trompeter RS, Tullus K, Winyard PJ, Cansick J, Mushtaq I, Dhillon HK, Bingham C, Edghill EL, Shroff R, Stanescu H, Ryffel GU, Ellard S, Bockenhauer D (2009) HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. *J Am Soc Nephrol* 20:1123–1131
50. van der Made CI, Hoom EJ, de la Faille R, Karaaslan H, Knoers NV, Hoenderop JG, Vargas Poussou R, de Baaij JH (2015) Hypomagnesemia as first clinical manifestation of ADTKD-HNF1B: a case series and literature review. *Am J Nephrol* 42:85–90
51. Ferre S, Veenstra GJ, Bouwmeester R, Hoenderop JG, Bindels RJ (2011) HNF-1B specifically regulates the transcription of the gamma-subunit of the Na⁺/K⁺-ATPase. *Biochem Biophys Res Commun* 404:284–290
52. Thony B, Neuheiser F, Kierat L, Blaskovics M, Arn PH, Ferreira P, Rebrin I, Ayling J, Blau N (1998) Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the PCBD gene encoding the bifunctional protein pterin-4a-carbinolamine dehydratase and transcriptional coactivator (DCoH). *Am J Hum Genet* 62:1302–1311
53. Ferre S, de Baaij JH, Ferreira P, Germann R, de Klerk JB, Lavrijsen M, van Zeeland F, Venselaar H, Kluijtmans LA, Hoenderop JG, Bindels RJ (2014) Mutations in PCBD1 cause hypomagnesaemia and renal magnesium wasting. *J Am Soc Nephrol* 25:574–586
54. Simaite D, Kofent J, Gong M, Ruschendorf F, Jia S, Am P, Bentler K, Ellaway C, Kuhnen P, Hoffmann GF, Blau N, Spagnoli FM, Hubner N, Raile K (2014) Recessive mutations in PCBD1 cause a new type of early-onset diabetes. *Diabetes* 63:3557–3564
55. Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and development. *Cell* 125:1241–1252
56. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP (2004) A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. *Science* 306:1190–1194
57. Belostotsky R, Ben-Shalom E, Rinat C, Becker-Cohen R, Feinstein S, Zeligson S, Segel R, Elpeleg O, Nassar S, Frishberg Y (2011) Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. *Am J Hum Genet* 88:193–200
58. Emma F, Pizzini C, Tessa A, Di Giandomenico S, Onetti-Muda A, Santorelli FM, Bertini E, Rizzoni G (2006) “Barter-like” phenotype in Kearns-Sayre syndrome. *Pediatr Nephrol* 21:355–360
59. Goto Y, Itami N, Kajii N, Tochimaru H, Endo M, Horai S (1990) Renal tubular involvement mimicking Bartter syndrome in a patient with Kearns-Sayre syndrome. *J Pediatr* 116:904–910
60. Kriz WK, B (1979) Structural analysis of the rabbit. *Kidney* 56(X):126
61. Corral-Rodriguez MA, Stuiver M, Abascal-Palacios G, Diercks T, Oyenarte I, Ereno-Orbea J, de Opakua AI, Blanco FJ, Encinar JA, Spiwok V, Terashima H, Accardi A, Muller D, Martinez-Cruz LA (2014) Nucleotide binding triggers a conformational change of the CBS module of the magnesium transporter CNNM2 from a twisted towards a flat structure. *Biochem J* 464:23–34
62. Harvey JN, Barnett D (1992) Endocrine dysfunction in Kearns-Sayre syndrome. *Clin Endocrinol (Oxf)* 37:97–103
63. Giordano C, Powell H, Leopizzi M, De Curtis M, Travaglini C, Sebastiani M, Gallo P, Taylor RW, d’Amati G (2009) Fatal congenital myopathy and gastrointestinal pseudo-obstruction due to POLG1 mutations. *Neurology* 72:1103–1105
64. Gilbert RD, Emms M (1996) Pearson’s syndrome presenting with Fanconi syndrome. *Ultrastruct Pathol* 20:473–475
65. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R, Sheffield VC (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nat Genet* 31:171–174
66. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M (2002) Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nat Genet* 31:166–170
67. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG (2004) TRPM6 forms the Mg²⁺ influx channel involved in intestinal and renal Mg²⁺ absorption. *J Biol Chem* 279:19–25
68. Anast CS, Mohs JM, Kaplan SL, Burns TW (1972) Evidence for parathyroid failure in magnesium deficiency. *Science* 177:606–608
69. Wang CY, Shi JD, Yang P, Kumar PG, Li QZ, Run QG, Su YC, Scott HS, Kao KJ, She JX (2003) Molecular cloning and characterization of a novel gene family of four ancient conserved domain proteins (ACDP). *Gene* 306:37–44
70. Stuiver M, Lainez S, Will C, Terryn S, Gunzel D, Debaix H, Sommer K, Kopplin K, Thumfart J, Kampik NB, Querfeld U, Willnow TE, Nemeč V, Wagner CA, Hoenderop JG, Devuyst O, Knoers NV, Bindels RJ, Meij IC, Muller D (2011) CNNM2, encoding a basolateral protein required for renal Mg²⁺ handling, is mutated in dominant hypomagnesaemia. *Am J Hum Genet* 88:333–343
71. Arjona FJ, de Baaij JH, Schlingmann KP, Lameris AL, van Wijk E, Flik G, Regele S, Korenke GC, Neophytou B, Rust S, Reintjes N, Konrad M, Bindels RJ, Hoenderop JG (2014) CNNM2 mutations cause impaired brain development and seizures in patients with hypomagnesaemia. *PLoS Genet* 10:e1004267
72. Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV, Bindels RJ (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesaemia. *J Clin Invest* 117:2260–2267
73. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van Cutsem E (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. *Lancet Oncol* 8:387–394
74. Campbell P, Morton PE, Takeichi T, Salam A, Roberts N, Proudfoot LE, Mellerio JE, Aminu K, Wellington C, Patil SN, Akiyama M, Liu L, McMillan JR, Aristodemou S, Ishida-Yamamoto A, Abdul-Wahab A, Petrof G, Fong K, Harnchoowong S, Stone KL, Harper JJ, McLean WH, Simpson MA, Parsons M, McGrath JA (2014) Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. *J Invest Dermatol* 134:2570–2578
75. Glaudemans B, van der Wijst J, Scola RH, Lorenzoni PJ, Heister A, van der Kemp AW, Knoers NV, Hoenderop JG, Bindels RJ (2009)

- A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. *J Clin Invest* 119:936–942
76. D'Adamo MC, Gallenmuller C, Servettini I, Hartl E, Tucker SJ, Aming L, Biskup S, Grottesi A, Guglielmi L, Imbrici P, Bernasconi P, Di Giovanni G, Franciolini F, Catacuzzeno L, Pessia M, Klopstock T (2014) Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene. *Front Physiol* 5:525
 77. Graves TD, Cha YH, Hahn AF, Barohn R, Salajegheh MK, Griggs RC, Bundy BN, Jen JC, Baloh RW, Hanna MG (2014) Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. *Brain* 137:1009–1018
 78. Ellison DH (2009) The voltage-gated K⁺ channel subunit Kv1.1 links kidney and brain. *J Clin Invest* 119:763–766
 79. Unger S, Goma MW, Le Behec A, Do Vale-Pereira S, Bedeschi MF, Geiberger S, Grigelioniene G, Horemuzova E, Lalatta F, Lausch E, Magnani C, Nampoothiri S, Nishimura G, Petrella D, Rojas-Ringeling F, Utsunomiya A, Zabel B, Pradervand S, Harshman K, Campos-Xavier B, Bonafe L, Superti-Furga G, Stevenson B, Superti-Furga A (2013) FAM111A mutations result in hypoparathyroidism and impaired skeletal development. *Am J Hum Genet* 92:990–995
 80. Bergada I, Schiffrin A, Abu Srair H, Kaplan P, Dorman J, Goltzman D, Henty GN (1988) Kenny syndrome: description of additional abnormalities and molecular studies. *Hum Genet* 80:39–42
 81. Fanconi S, Fischer JA, Wieland P, Atares M, Fanconi A, Giedion A, Prader A (1986) Kenny syndrome: evidence for idiopathic hypoparathyroidism in two patients and for abnormal parathyroid hormone in one. *J Pediatr* 109:469–475
 82. Isojima T, Doi K, Mitsui J, Oda Y, Tokuhiko E, Yasoda A, Yorifuji T, Horikawa R, Yoshimura J, Ishiura H, Morishita S, Tsuji S, Kitanaka S (2014) A recurrent de novo FAM111A mutation causes Kenny-Caffey syndrome type 2. *J Bone Miner Res* 29:992–998
 83. Lee WK, Vargas A, Barnes J, Root AW (1983) The Kenny-Caffey syndrome: growth retardation and hypocalcemia in a young boy. *Am J Med Genet* 14:773–782
 84. Nikkel SM, Ahmed A, Smith A, Marcadier J, Bulman DE, Boycott KM (2014) Mother-to-daughter transmission of Kenny-Caffey syndrome associated with the recurrent, dominant FAM111A mutation p.Arg569His. *Clin Genet* 86:394–395
 85. Yorifuji T, Muroi J, Uematsu A (1998) Kenny-Caffey syndrome without the CATCH 22 deletion. *J Med Genet* 35:1054
 86. Fine DA, Rozenblatt-Rosen O, Padi M, Korkhin A, James RL, Adelmant G, Yoon R, Guo L, Berrios C, Zhang Y, Calderwood MA, Velmurgan S, Cheng J, Marto JA, Hill DE, Cusick ME, Vidal M, Florens L, Washburn MP, Litovchick L, DeCaprio JA (2012) Identification of FAM111A as an SV40 host range restriction and adenovirus helper factor. *PLoS Pathog* 8:e1002949
 87. Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen GK, Le Marchand L, Kolonel LN, Katoh T, Yamano Y, Yamakado M, Takahashi H, Yamada H, Egawa S, Fujioka T, Henderson BE, Habuchi T, Ogawa O, Nakamura Y, Nakagawa H (2012) Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. *Nat Genet* 44:426–429, S421
 88. Houston SK, Pina Y, Clarke J, Koru-Sengul T, Scott WK, Nathanson L, Scheffler AC, Murray TG (2011) Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. *Invest Ophthalmol Vis Sci* 52:5359–5368
 89. Singh H, Farouk M, Bose BB, Singh P (2013) Novel genes underlying beta cell survival in metabolic stress. *Bioinformatics* 9:37–41
 90. Serna M, Carranza G, Martin-Benito J, Janowski R, Canals A, Coll M, Zabala JC, Valpuesta JM (2015) The structure of the complex between alpha-tubulin, TBCE and TBCB reveals a tubulin dimer dissociation mechanism. *J Cell Sci* 128:1824–1834
 91. Parvari R, Hershkovitz E, Grossman N, Gorodischer R, Loeys B, Zecic A, Mortier G, Gregory S, Sharony R, Kambouris M, Sakati N, Meyer BF, Al Aqeel AI, Al Humaidan AK, Al Zahrani F, Al Swaid A, Al Othman J, Diaz GA, Weiner R, Khan KT, Gordon R, Gelb BD (2002) Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. *Nat Genet* 32:448–452
 92. Topf JM, Murray PT (2003) Hypomagnesemia and hypermagnesemia. *Rev Endocr Metab Disord* 4:195–206
 93. Gullestad L, Oystein Dolva L, Birkeland K, Falch D, Fagertun H, Kjekshus J (1991) Oral versus intravenous magnesium supplementation in patients with magnesium deficiency. *Magn Trace Elem* 10:11–16
 94. Haas M, Wang H, Tian J, Xie Z (2002) Src-mediated inter-receptor cross-talk between the Na⁺/K⁺-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. *J Biol Chem* 277:18694–18702
 95. Reichold M, Zdebek AA, Lieberer E, Rapedius M, Schmidt K, Bandulik S, Sterner C, Tegtmeier I, Penton D, Baukrowitz T, Hulton SA, Witzgall R, Ben-Zeev B, Howie AJ, Kleta R, Bockenhauer D, Warth R (2010) KCNJ10 gene mutations causing EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt channel function. *Proc Natl Acad Sci USA* 107:14490–14495
 96. Terker AS, Zhang C, McCormick JA, Lazelle RA, Zhang C, Meermeier NP, Siler DA, Park HJ, Fu Y, Cohen DM, Weinstein AM, Wang WH, Yang CL, Ellison DH (2015) Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. *Cell Metab* 21:39–50